Status:
COMPLETED
Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis
Lead Sponsor:
Amgen
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in the treatment of Rheumatoid Arthritis (RA).
Eligibility Criteria
Inclusion
- Diagnosis of RA.
- All subjects will be required to have been taking a stable dose of methotrexate.
- Active RA at screening defined as greater than or equal to 6 swollen joints.
- The presence of erosive disease
Exclusion
- Received any biologic agent (e.g., Enbrel®, Remicade®, Humira®, Kineret®) or Arava® within 8 weeks before randomization; past use of these agents is allowed.
- Steroid use greater than 15 mg/day.
- Scheduled for surgery or joint replacement in the hands, wrists or feet.
Key Trial Info
Start Date :
August 11 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
227 Patients enrolled
Trial Details
Trial ID
NCT00095498
Start Date
August 11 2004
End Date
April 1 2007
Last Update
October 25 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.